Clinical Trials Logo

ALK-POSITIVE NSCLC clinical trials

View clinical trials related to ALK-POSITIVE NSCLC.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT05482087 Not yet recruiting - ALK-positive NSCLC Clinical Trials

A Study of XZP-3621 in Chinese Patients With ALK Positive NSCLC

Start date: September 2022
Phase: Phase 2
Study type: Interventional

This was a single-arm, open-label, multicenter, phase II study to evaluate the efficacy and safety of the ALK inhibitor XZP-3621 when used as single agent in patients with ALK-rearranged stage IIIB, IIIC or IV NSCLC previously treated with other ALK inhibitors or non-previously treated.